Peer-reviewed veterinary case report
Using PET/CT scans to predict survival in dogs with bone cancer
By Martin, Tiffany W & Griffin, Lynn·Published in Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2024·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prospective pilot study utilizing changes in quantitative values obtained on serial fluorine-18 fluorodeoxyglucose (F-FDG) positron emission tomography-computed tomography (PET/CT) in dogs with appendicular osteosarcoma before and after stereotactic body radiation therapy (SBRT) and carboplatin chemotherapy to assess for prediction of survival and therapeutic effectiveness.
- Species:
- dog
Plain-English summary
A group of 14 dogs with bone cancer (appendicular osteosarcoma) underwent treatment with radiation therapy and chemotherapy. They had scans before and after treatment to see how well the cancer responded. The results showed a significant decrease in cancer activity, with many dogs showing over 99% reduction in tumor volume. The scans helped predict which dogs were more likely to develop metastasis (spread of cancer) and how long they might survive. This suggests that these imaging tests can be useful for monitoring treatment effectiveness in dogs with this type of cancer.
People also search for: dog bone cancer treatment · osteosarcoma in dogs prognosis · radiation therapy for dog cancer
Abstract
Serial fluorine 18 fluorodeoxyglucose (F-FDG) positron emission tomography-CT (PET/CT) is commonly used in human oncology to prognosticate and evaluate for therapeutic effectiveness. In this pilot study, dogs with naturally occurring appendicular osteosarcoma were evaluated with serialF-FDG PET/CT in an attempt to assess for response to therapy, prognostic factors, and appropriateness of imaging intervals. Fourteen dogs were enrolled in the trial. All dogs had the initialF-FDG PET/CT (PET1), with nine dogs having their end-of-therapyF-FDG PET/CT (EoT PET) 3 months after stereotactic body radiation therapy (SBRT) to the primary tumor. The median percent change from the PET1 to the EoT PET for the standard uptake value maximum (SUV) was -58% (range: -17 to -88%), metabolic tumor volume (MTV) was -99.8% (range: -65 to -100%), and total lesion glycolysis (TLG) was -99.8% (range: -75 to -100%), all of which were significant (P < .05, <.05, and <.05, respectively). On evaluation, it was found that volumes of GTV and CTV were significant for survival (P < .05 and <.05), MTV, TLG, and SUVon the EoT PET (SUV) were predictive of metastasis (P < .05), and the SUVwas significantly correlated to the time to first event (P < .05). Based on this data, serialF-FDG PET/CT performed 3 months after SBRT can show a significant reduction in avidity, and the quantitative data collected may help predict metastatic disease in canine appendicular osteosarcoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38655687/